Recombinant leptin therapy helps improve insulin sensitivity, reduce circulating triglyceride concentrations, and decrease liver volume in patients with lipodystrophy; however, leptin therapy does not adequately address all the metabolic perturbations for reasons that are incompletely understood (13). This evidence concerns the gene INS and lipodystrophy.